Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday.

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic ...

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Global health highlights include a court pausing a generic version of a heart drug, Novo Nordisk's weight loss trial success, ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Investing.com -- Shares of Novo Nordisk (NYSE: NVO) fell 2% following the announcement of results from its STEP UP obesity trial, which showed that Semaglutide 7.2 mg achieved a 20.7% weight loss in ...